Are you providing adequate ventilation for your storage and production areas?

A company recently received this 483 observation:

….. Adequate ventilation is not provided.

Specifically, your firm has failed to establish appropriate temperature and humidity controls and monitoring in storage and production areas that may impact the quality of drugs which are incorporated into medical kits such as …. There are no records maintained to demonstrate that drugs received, stored, and assembled into medical kits have been stored in a manner to ensure the identity, strength, quality, and purity. The facility temperature observed during the inspection  was 80°F and 79°F (observed on wall thermometer in medical kit assembly production room). Your firm reportedly receives and stores drugs for up to 12 weeks prior to kit assembly and may hold finished assembled kits for up to 2 days prior to distribution to customers.

For more observations pertaining to manufacturing controls, see Issue 1042 available today.  It also has observations pertaining to lab controls, sterile manufacturing controls and medical device manufacturers.

Stay in Compliance! Subscribe today!

Become A Subscriber And Stay Ahead of the FDA

To get the most out of GMP Trends®, sign up to one of our subscription packages for valuable, up-to-date information you won't find anywhere else! Every subscription provides the most frequently cited FDA 483 observations taken from recent FDA Inspections. The non-essential information is redacted to streamline the facts in an easily readable format. Join the thousands of professionals who rely on GMP Trends® to keep them informed of the latest FDA Enforcement Trends!

SUBSCRIBE NOW